Table 3.

Glucose metabolism targets and drugs which are in preclinical and clinical development for anti-tumor therapy

Target	Drug	Status	References
GLUTs	Phloretin	Preclinical	[99,100]
	Fasentin	Preclinical	[101]
	STF-31	Preclinical	[102]
	WZB117	Preclinical	[103]
	Ritonavir	Phase III	[104]
	Silybin	Phase I	[105]
HKII	2-Deoxy-D-glucose	Phase II	[106,107]
	Lonidamine	Phase II	[108]
	Genistein-27	Preclinical	[109]
	Benserazide	Preclinical	[110]
	Resveratrol	Phase I	[111]
	Astragalin	Preclinical	[25]
	Chrysin	Preclinical	[112]
PDK	Dichloroacetate	Phase I	[113-115]
LDHA	Oxamate	Preclinical	[116]
	FX11	Preclinical	[117]
	Quinoline-3-sulfonamide	Preclinical	[118]
	GNE-140	Preclinical	[119]
	PSTMB	Preclinical	[120]
PKM2	Shikonin	Preclinical	[121]
	Benserazide	Preclinical	[122]
PFKFB	3PO	Preclinical	[123]
	PFK158	Preclinical	[124]
GAPDH	Bromopyruvate	Preclinical	[125]
IDH	Enasidenib	Approved	[126]
	Ivosedinib	Approved	[127]
	DS-1001b	Preclinical	[128]
	Olutasidenib	Preclinical	[129]
	GSK864	Preclinical	[130]
	BAY1436032	Preclinical	[131]
	HMS-101	Preclinical	[132]
	I-8	Preclinical	[133]

Abbreviations: GLUT: Glucose transporters; HK: Hexokinase; PDK: Pyruvate dehydrogenase kinase; LDHA: Lactate dehydrogenase A; PKM2: Pyruvate kinase M2; PFKFB3: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; GAPGH: glyceraldehyde-3-phosphate dehydrogenase; IDH: Isocitrate dehydrogenase.